By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.

HEPLISAV-B™ - Our Lead Product Candidate

HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.

SD-101 - Cancer Immunotherapy

We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.

Immune-Mediated Diseases

TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma

Key Statistics

Ownership: Public

Web Site: Dynavax Technologies Corporation
Symbol: DVAX

Company News
Dynavax Technologies Corporation (DVAX) Reports Third Quarter 2015 Financial Results 11/5/2015 11:33:10 AM
Dynavax Technologies Corporation (DVAX) Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 In Combination With Merck & Co. (MRK)'s Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab) 10/8/2015 10:40:55 AM
Dynavax Technologies Corporation (DVAX) To Participate In Two Upcoming Investor Conferences 9/3/2015 10:39:56 AM
Dynavax Technologies Corporation (DVAX) Reports Second Quarter 2015 Financial Results 8/10/2015 8:44:25 AM
Dynavax Technologies Corporation (DVAX) Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock 7/28/2015 9:43:44 AM
Dynavax Technologies Corporation (DVAX) Prices Public Offering Of Common Stock 7/22/2015 10:38:05 AM
Dynavax Technologies Corporation (DVAX) Announces Third Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B(TM) And Updates Financial Status 7/9/2015 8:46:35 AM
Dynavax Technologies Corporation (DVAX) To Present At The William Blair 35th Annual Growth Stock Health Care Conference 6/9/2015 10:59:27 AM
Merck & Co. (MRK) And Dynavax Technologies Corporation (DVAX) Announce New Collaboration Investigating The Combination Of Immuno-Oncology Therapies 6/1/2015 10:27:19 AM
Dynavax Technologies Corporation (DVAX) Reports First Quarter 2015 Financial Results 5/8/2015 9:53:02 AM